What's breaking now, across thousands of outlets.
Attovia Therapeutics Inc., an early-stage drug developer focused on immune system diseases with high unmet need, raised $289 million in a US initial public offering that priced at the top of its marketed range.
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
This is one outlet's version. Read the fullest account.
'Strange nights' (4/7). This little-known phenomenon is characterized by intense, continuous dreams, non-restorative sleep, and daytime fatigue. It was first described by two American doctors in 1995.
The pharmaceutical manufacturer wants to accelerate its overseas growth while broadening its portfolio beyond its traditional strength in infectious disease medications.
The power of social influence could be key to changing attitudes and behaviors around climate change, according to a new study by researchers at the Center for Climate Change and Social…
The outbreak is the biggest ever to have hit the Democratic Republic of Congo, despite being declared less than three months ago.
Regan Odysseus was scared. She'd tried Prozac before, but the medication made her mental health worse, leaving her unsure whether further treatment would help or hurt.
Building a highly technical, highly regulated pharmaceutical facility takes years, and we are in the part of the cycle where the work is physical, not scientific.
